September 21, 2016

Verseon Corporation (“Verseon” or the “Company”)

Director/PDMR Shareholding

Verseon, a technology-based pharmaceutical company, has received notification that Eniko Fodor, the Chief Operating Officer and Chief Financial Officer of the Company, has purchased 6,000 common shares of par value $0.001 each in the Company (“Common Shares”) at a purchase price of £1.61 per Common Share.

Following the purchase, Ms. Fodor will hold 31,008,486 Common Shares, representing approximately 20.5% of the Company's issued share capital.


For further information please contact:

Verseon Corporation +1 (510) 225 9000
Arthur Shmurun / Amy Thai
Cenkos Securities (NOMAD and Broker) +44 (0) 20 7397 8900
Mark Connelly / Steve Cox  
Buchanan Communications Ltd (PR Advisors) +44 (0) 20 7466 5000
Henry Harrison-Topham / Sophie Cowles
1Details of the person discharging managerial responsibilities / person closely associated
a)NameEniko Fodor
2Reason for the notification
a)Position/statusDirector and Officer
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameVerseon Corporation
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument

Identification code
Common Shares of par value $0.001

ISIN: USU9221J1098
b)Nature of the transactionPurchase of Common Shares
c)Price(s) and volume(s)
d)Aggregated information
— Aggregated volume
— Price

e)Date of the transaction19 September 2016
f)Place of the transactionN/A

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen